Explore the full record of transactions filed by paolo rampulla, Director Representing Santé Holdings at CARMAT. Insider active across 2 companies, notably ABIVAX. In total, 2 reports have been recorded. Total volume traded: €40. The latest transaction was filed on 2 October 2024 — Souscription. Regulator: AMF. The full history is accessible without signup.
2 of 2 declarations
Paolo Rampulla is an Italian corporate and tax specialist best known for his role at CARMAT, where he serves as Director representing Santé Holdings on the Board of Directors. In CARMAT’s governance materials, he is described as a well-regarded tax expert with a strong focus on mergers and acquisitions, private equity, international taxation, and the taxation of financial instruments. His experience is particularly relevant in the healthcare and life sciences sectors, as well as in automotive and oil and gas, giving him a broad cross-industry perspective that is valuable in board-level oversight. Rampulla’s academic background combines economics and tax law. He holds a degree in Economics from the University Luigi Bocconi in Milan and a Master in Tax Law from the Ipsoa School in Milan. This training supports a career built at the intersection of finance, law, and corporate strategy. His profile suggests deep familiarity with complex transactions, cross-border structures, and the fiscal implications of strategic decisions, which are central skills for a board member in a listed company environment. At CARMAT, his role is especially important in a company operating in the highly regulated medical devices sector. Strategic choices around funding, capital structure, partnerships, governance, and risk management require directors with strong financial and legal judgment. As a representative of Santé Holdings, Rampulla contributes to board deliberations on governance and long-term positioning, bringing an investor-oriented and structurally disciplined approach to decision-making. More broadly, Paolo Rampulla stands out as a governance professional whose expertise is likely to be most valuable in periods of transformation, fundraising, restructuring, or international expansion. His board presence at CARMAT reflects the importance of specialized fiscal and transaction expertise in supporting innovative listed companies as they navigate demanding operational and regulatory environments.